載入...
Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis
Introduction: China has ~6 million patients with active epilepsy every year, around 60% of whom suffer from partial-onset seizures. Perampanel (PER) is a novel anti-epileptic drug for partial-onset seizures. PER has been included in the latest Chinese National Reimbursement Drug List (NRDL) in 2020....
Na minha lista:
| 發表在: | Front Public Health |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8290415/ https://ncbi.nlm.nih.gov/pubmed/34295868 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fpubh.2021.670108 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|